Novavax, Inc. is a biotechnology company that discovers, develops and commercializes vaccines to prevent serious infectious diseases. The company offers a differentiated vaccine platform that combines a recombinant protein-based approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance immune response. It has a commercial program, for COVID-19 vaccines, which includes the Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and the updated Nuvaxovid COVID-19 vaccine (NVX-CoV2601 or vaccine updated) (collectively, the COVID-19 vaccine). The Company is continuing the development of other vaccine candidates, including its COVID19-combined influenza (CIC) vaccine candidate and other vaccine candidates. The COVID-19 vaccine and its other vaccine candidates incorporate the company’s proprietary Matrix-M adjuvant to enhance the immune response, stimulate higher levels of functional antibodies, and induce a cellular immune response.
More information about the company
